Affordable Access

Molecular pharmacology of LR-B/081, a new non-peptide angiotensin AT1 receptor antagonist.

Authors
Type
Published Article
Journal
European Journal of Pharmacology
0014-2999
Publisher
Elsevier
Publication Date
Volume
290
Issue
2
Pages
151–156
Identifiers
PMID: 8575530
Source
Medline

Abstract

This report describes the molecular pharmacological properties of LR-B/081 (methyl 2-[[4-butyl-2-methyl-6-oxo-5-[[2'-(1H-tetrazol-5- yl) [1,1'-biphenyl]-4-yl]methyl]-1 (6H)-pyrimidinyl]methyl]- 3-thiophenecarboxilate), a novel non-peptide angiotensin II receptor antagonist. This compound potently displaced [3H]angiotensin II from angiotensin AT1 (Ki = 1.4 nM, rat adrenal cortex), but not from angiotensin AT2 (Ki > 1 microM, bovine cerebellar cortex) receptors and did not show affinity for other receptor systems (Ki > 10 microM). In saturation studies, LR-B/081 both increased KD and decreased Bmax values in a dose-dependent fashion. The rate of dissociation of [3H]angiotenin II from angiotensin AT1 receptors was not affected by the presence of 1 microM LR-B/081 and the association rate of [3H]angiotensin II was not decreased by the presence of 1 or 30 nM LR-B/081, indicating that the Bmax reduction was not due to an allosteric interaction or to a delay in reaching the steady-state conditions. These data underline the complexity of the antagonistic nature of LR-B/081, presenting features of both competitive and noncompetitive antagonism.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments